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bstract
Potential therapeutic benefits of seaweed consumption have been reported in the management of body weight and obesity. In  vitro  and in  vivo
nimal studies provide the majority of data available at present. The majority of studies assessing the short-term effects of alginate consumption
ndicate that alginate may increase satiety, reduce energy intake and support weight reduction. Mechanisms suggested for these effects include
elayed gastric clearance, stimulation of gastric stretch receptors and attenuated nutrient absorption. Long-term studies in humans are required
n order to allow firm conclusions. Animal studies have investigated potential anti-obesity effects of seaweeds on adipogenesis and the inhibition
f major lipid hydrolyzing and metabolizing enzymes. The results of these studies suggest beneficial effects of seaweed components such as
ucoxanthin on body weight and the percentage of abdominal white adipose tissue. It is premature to extrapolate these findings to humans since
onsistent findings are still lacking. There is at present no solid evidence indicating that seaweeds are effective in long-term weight management.
owever, available findings suggest potential benefits of seaweed components on obesity. Future investigations are required to establish theherapeutic efficacy in the management of overweight and obesity in humans and elucidate the underlying mechanisms of actions.
 2015 Beijing Academy of Food Sciences. Production and hosting by Elsevier B.V. All rights reserved.
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s.  Introduction
Obesity is a metabolic disorder and can be defined as
ncreased body weight caused by excessive fat accumulation
hich presents a risk to health with an increase in health
roblems and/or reduced life expectancy [1,2]. Obesity is
haracterized by an increased storage of triglycerides in adipose
issues. In obese individuals, there is an increase in the inci-
ence of various diseases such as cardiovascular disease, type 2
iabetes, certain types of cancer, and osteoarthritis [1]. Obesity
as reached epidemic proportions in developed countries and
s also increasing in developing countries [3]. The epidemic is
 leading preventable cause of death worldwide and has been
uggested to be one of the most serious public health problems∗ Corresponding author at: Department of Experimental Psychology, Univer-
ity of Regensburg, 93040 Regensburg, Germany. Tel.: +49 941 9433815;
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213-4530/© 2015 Beijing Academy of Food Sciences. Production and hosting by Ef the 21st century [4]. In 2008, 35% of adults aged 20 or more
ere overweight (body mass index ≥25 kg/m2) [5]. The world-
ide prevalence of obesity has nearly doubled between 1980
nd 2008. In 2008, 10% of men and 14% of women in the world
ere obese (BMI ≥30 kg/m2), compared with 5% for men and
% for women in 1980 [5]. An estimated total of more than half
 billion adults over the age of 20 were obese. The prevalence of
besity was highest in the WHO Regions of the Americas (26%
n both sexes) and lowest in the WHO Region for South East Asia
3% in both sexes) [5]. Worldwide, at least 2.8 million people
ie each year as a result of being overweight or obese, and an
stimated 35.8 million (2.3%) of global disability-adjusted life
ears are caused by overweight or obesity [5].
Obesity is most commonly caused by a combination of exces-
ive food energy intake, lack of physical activity, and genetic
usceptibility. The epidemic reflects progressive secular and
ge-related decreases in physical activity, together with substan-
ial dietary changes with passive over-consumption of energy
espite the neurobiological processes controlling food intake
1]. The main treatments for obesity are dieting and exercising.
lsevier B.V. All rights reserved.
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ffective long-term weight loss depends on permanent changes
n dietary quality, energy intake, and physical activity [1].
iet quality can be improved by reducing the consumption of
nergy-dense foods and by increasing the intake of dietary fiber.
owever, behavioral interventions alone have been inconsistent
n promoting sufficient and sustained weight loss. The identi-
cation of substances that are able to decrease or even prevent
besity has become a major goal of research. Consequently,
harmacological research has focused on the development of
nti-obesity medications which may reduce appetite or decrease
at absorption [6]. Due to high costs and potentially hazardous
dverse effects of these drugs, researchers have become inter-
sted in finding safe and therapeutically effective anti-obesity
ompounds derived from natural products [7], such as seaweeds.
Seaweeds are marine macroalgae and various seaweed types
ave traditionally been used as food additives or flavoring mate-
ials in many countries. For example, the Japanese use 88
eaweed species in cuisine and as healthcare foods according to
he KNApSAcK Lunch Box Database [8–11]. Seaweeds are rich
n minerals (e.g. iodine, magnesium, iron, zinc and calcium) and
ietary fibers and are consumed mainly in East Asia, e.g., Japan,
hina, Korea, etc. In Japan, for example, over 20 species of red
Rhodophyta), green (Chlorophyta), and brown (Phaeophyta)
lgae are popular in meals [12]. The three most common sea-
eed products in Japan are nori (Porphyra, 33 species), wakame
Undaria, 2 species) and kombu (Laminaria, 12 species).
Seaweed is served in approximately 21% of meals in Japan
13], with 20–38% of the population aged 40–79 years consum-
ng seaweed more than five times per week, 29–35% three to four
imes per week, 25–35% one to two times per week, 6–13% one
o two times per month, and 1–2% rarely consuming seaweed
14]. Estimating the amount of seaweed consumption is difficult
ue to dietary differences between age groups and geographi-
al regions. Seaweed consumption has been estimated to vary
etween 4 and 7 g/day dried weight [12,15–17] and 12 g/day
sing both dry and wet weight [18]. Daily seaweed consumption
er person in Japan has been reported to have remained relatively
onsistent between 1955 (4.3 g/day) and 1995 (5.3 g/day) [15],
hile the type of seaweed consumed changed over 40 years with
n increase in the intake of wakame and nori and a decrease in
ombu consumption [19].
Seaweeds contain a variety of potentially bioactive com-
ounds some of which are not present in terrestrial plants.
hese compounds include, for example, proteins such as
ectins or phycobiliproteins, carotenoids, pigments, polyphe-
ols, phlorotannins and certain polysaccharides. They may
ave health-promoting properties and play a role in modulating
hronic disease [20]. Epidemiological studies comparing South-
ast Asian and Western-style diets have reported an association
etween dietary intake of seaweeds and a reduced prevalence
f chronic diseases including cardiovascular disease, hyper-
ipidemia and cancer [21,22]. In Japan, the recent spread of
 Western diet including an increase in the consumption of
eat and dairy products has coincided with an increase in the
ncidence of chronic diseases [23,24]. A reduction in regular
eaweed consumption and other dietary changes are particularly
bvious in young Japanese people [14,25].
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.  Effects  of  seaweed  ﬁber  on  appetite  and  body  weight
A diet rich in fiber has been demonstrated to prolong the
astric emptying rate and thereby increasing satiety and reduc-
ng food consumption [26]. Since seaweeds are a good source
f dietary fiber [27] several studies have assessed the ability
f sodium alginate extracted from brown seaweed to enhance
atiety and to decrease energy intake (see Table 1).
Pelkman and her colleagues [28] tested the effects of a novel
everage, consisting of alginate-pectin and calcium components,
hich forms a stable, fibrous gel in the stomach, on subjective
atiety and food intake in overweight and obese women (see
able 1). Twenty-nine individuals drank a 2-part beverage twice
er day (once before breakfast and once midafternoon) for 7
ays. Three alginate-pectin formulations were tested, i.e. 1.0 g,
.8 g, and control without fiber. Subjective satiety and ad libitum
ood intake were measured on days 1 and 7 of each 1-week treat-
ent period with a 1-week washout between testings. A decrease
n energy consumption was observed in overweight and obese
omen with low dietary restraint following a 7-day supplemen-
ation with alginate-pectin drinks compared to a control drink.
ncreased stimulation of endogenous satiety signaling is sup-
osed to be the reason for the decrease in energy intake [28].
uture research needs to assess how dietary restraint affects this
bservation.
Paxman et al. [29] investigated the effects of alginate on
ppetite control in free-living healthy normal-weight, over-
eight and obese adults using a randomized, controlled two-way
rossover intervention (see Table 1). They compared the effects
f a 7-day daily intake of a strong-gelling sodium alginate for-
ulation with a control group. Daily preprandial ingestion of
odium alginate led to a significant reduction by 7% (134.8 kcal)
n mean daily energy intake. In addition, significant reductions
n the mean daily ingestion of carbohydrate, fat, saturated fat
nd protein were found [29]. These results suggest a role for a
trong-gelling sodium alginate in the treatment of overweight
nd obesity. The potential efficacy of this therapeutic approach
or individuals in different settings was suggested by the absence
f any significant interaction effects between the main effect of
reload type and those of gender, classification of body mass
ndex and/or timing of preload delivery.
In a further crossover study performed by Paxman and
olleagues [30], the uptake of glucose, cholesterol, and triacyl-
lycerols in humans with normal and high body mass index
as investigated (see Table 1). The uptake of these substances
ncreased with increasing body fat. The administration of a bev-
rage containing 1.5 g of strong-gelling alginate restored uptake
f glucose and cholesterol in overweight and obese subjects to
he levels of healthy participants whose uptake was not affected
y the alginate drink. This data also indicates a potential efficacy
f gelling fibers.
Jensen and his co-authors [31] studied the effects on postpran-
ial satiety feelings, energy intake, and gastric emptying rate, of
wo different volumes of an alginate-based preload in normal-
eight subjects (see Table 1). Twenty individuals were randomly
ssigned to receive a 3% preload concentration of either low vol-
me (9.9 g alginate in 330 mL) or high volume (15.0 g alginate
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Table 1
Effects of seaweed fiber on body weight, overweight and obesity in humans.
Authors Subjects Substance Study design Study duration Dependent variables Results Major limitations
Pelkman et al.
[28]
Overweight
and obese
women
(n = 29)
Alginate Within-subjects, double-blind,
placebo-controlled crossover
trial.
3 conditions: 1.0 g/drink,
2.8 g/drink or no alginate
(control).
2 test drinks daily for 7 days. 1
week washout.
5 weeks Energy intake on days
1 and 7
Decrease in energy intake
for both active
formulations compared to
control group.
Short study duration,
only 1 dependent
variable assessed
Paxman et al.
[29]
Healthy men
and women
(n = 68)
Sodium
alginate from
brown algae
Randomized, controlled two-way
crossover study.
Preprandial 1.5 sodium alginate
beverage or control drink for 7
days. 2-Week washout phase.
Crossover
4 weeks Energy intake Decrease in daily energy
intake in sodium alginate
group.
Short study duration,
only 1 dependent
variable assessed
Paxman et al.
[30]
Healthy men
(n = 14)
Sodium
alginate from
brown algae
Crossover study.
1.5 g sodium alginate beverage or
control drink 3 hours after set
breakfast before test lunch. 7
days washout. Crossover
1 day
measurement
Pre- and postprandial
plasma levels of
glucose,
triacylglycerols and
cholesterol
Decrease in glucose and
cholesterol uptake in
participants of sodium
alginate group with
higher body mass index.
Small sample size,
only 1 timepoint
measured
Odunsi et al.
[34]
Overweight
and obese
male and
female
subjects
(n = 48)
Alginate
(brown
seaweed
Laminaria
digitata)
Randomized, parallel,
placebo-controlled,
allocation-concealed study.
3 alginate or control capsules per
day before meals for 7 days. 6
capsules on days 8–10.
10 days Gastric emptying,
gastric volume,
satiation, calorie
intake, gut hormones
No group effect of
treatment on any
dependent variable.
Georg Jensen
et al. [32]
Obese subjects
(n = 24)
Alginate Randomized, controlled
intervention study.
3% alginate 500 mL drink or
placebo 500 mL drink. 3 times
preload drink per day before
meals as an adjuvant to a
calorie-restricted diet.
2 weeks Weight loss Weight loss in both
groups due to calorie
restriction but not
enhanced by alginate
supplementation.
Short study duration,
small sample size
Georg Jensen
et al. [31]
Normal-
weight men
(n = 10) and
women
(n = 10)
Alginate Randomized placebo-controlled,
double-blind, four-way crossover
trial.
4 conditions: Low volume
alginate (9.9 g) 330 mL drink,
high volume alginate (15 g)
500 mL drink, 330 mL control
drink or 500 mL control drink.
1 day each on four
occasions
Energy intake, satiety
feelings, hunger
Low volume-alginate
drink reduced energy
intake, high volume
alginate drink increased
satiety and reduced
hunger.
Short study duration
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Table 1 (Continued)
Authors Subjects Substance Study design Study duration Dependent variables Results Major limitations
Georg Jensen
et al. [33]
Obese men
and women
(n = 96)
Alginate Randomized, double-blind,
placebo-controlled study.
3% alginate 500 mL drink or
placebo 500 mL drink. 3 times
preload drink per day before
meals as an adjuvant to a
calorie-restricted diet.
12 weeks Weight loss and
metabolic risk
markers (plasma
glucose, insulin,
C-reactive protein,
ghrelin, HOMA-IR,
lipid metabolism)
Weight loss in alginate
group greater than in
placebo group mainly due
to reduced body fat. No
change in metabolic risk
markers.
Hall et al. [39] Healthy
overweight
men (n = 12)
Ascophyllum
nodosum
Single blind crossover study.
100 g of bread containing
Ascophyllum nodosum (4%) or
no seaweed
1 day
measurement
Energy intake, plasma
glucose and
cholesterol
Decrease in energy intake
at meal 4 hours following
administration of
Ascophyllum nodosum
bread.
No changes in plasma
glucose and cholesterol
levels
Measurement at one
time point only
El Khoury
et al. [38]
Healthy men
(n = 24)
Alginate Randomized crossover study.
325 mL drinks of chocolate milk,
1.25% alginate chocolate milk,
2.5% alginate chocolate milk or
2.5% alginate solution 2 hours
before an ad libitum meal
1 day
measurement
Energy intake,
appetite, plasma
glucose and insulin
No group differences in
energy intake. 2.5%
alginate chocolate milk
reduced peak glucose
levels compared to 1.25%
alginate chocolate milk
and chocolate milk alone.
Insulin peaks reduced
after 2.5% alginate
chocolate milk compared
to chocolate milk.
Alginate chocolate milk
reduced pre-meal
appetite. 2.5% alginate
chocolate milk reduced
appetite compared to
chocolate milk alone.
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n 500 mL) alginate-based beverage, or an iso-volume placebo
rink. The preloads were consumed 30 min before a fixed break-
ast and again before an ad libitum lunch. The ingestion of low
olume-alginate preload induced a significant decrease (8.0%)
n energy intake compared to the placebo drink at the follow-
ng lunch meal, while differences in satiety feelings were not
bserved. The high volume-alginate induced a non-significant
eduction in energy consumption by only 5.5% although a signif-
cant increase in satiety feelings, reduced hunger and the feeling
f prospective food consumption was reported [31]. These find-
ngs suggest that alginate consumption can affect satiety feelings
nd energy intake.
In a pilot study, Jensen et al. [32] investigated in obese
articipants the effects on body weight loss and gastrointesti-
al tolerance of consuming low viscous alginate fiber-based
reloads of 3% concentration (500 mL volume) three times a day
s an adjuvant to a calorie-restricted diet (see Table 1). The intake
f the alginate preloads was moderately acceptable to the major-
ty of subjects but did not produce additional body weight loss
eyond calorie restriction in comparison to the control group.
hese findings do not suggest that alginate supplementation can
nhance the weight loss following a hypo-caloric diet [32].
Jensen et al. [33] repeated the study using a larger sample (see
able 1) and investigated the effects of alginate supplementation
n conjunction with energy restriction (−300 kcal/day) on loss
f body weight and on several metabolic risk markers. In con-
unction with an energy-restricted diet either an alginate-based
reload supplement (15 g fiber) or a placebo preload supplement
ere administered. The preload drinks were given 3 times a day
efore main meals for 12 weeks. At completion of trial, a greater
eight loss was observed with alginate than with placebo. This
as mainly attributed to a reduction in the percentage of body
at. Differences in plasma concentrations of glucose, insulin, C-
eactive protein, ghrelin, HOMA-IR, and lipid metabolism were
ot found [33]. These results suggest that alginate administra-
ion as an adjunct to energy restriction may improve weight loss
ue to alterations in body fat mass in obese subjects who com-
lete a 12-week dietary alginate intervention as an adjuvant to a
alorie-controlled diet.
The positive effects of alginate supplementation on weight
anagement reported previously have been challenged by find-
ngs of Odunsi et al. [34]. These authors analyzed the effects of
 10-day treatment with alginate or placebo on gastric functions,
atiation, appetite and gut hormones associated with satiety in
verweight or obese adults without psychiatric co-morbidity or
inge eating disorder (see Table 1). In all participants, gastric
mptying, fasting and postprandial gastric volumes, postprandial
atiation, calorie intake at a free choice meal and gut hormones
ghrelin, CCK, GLP-1, PYY) were measured after 1 week of
lginate (3 capsules versus placebo per day, ingested 30 min
efore the main meal). Six capsules were ingested with 30 min
efore the gastric emptying and the gastric volume and satia-
ion tests on days 8–10. Group effects of treatment were not
ound in regard to gastric emptying or volumes, gut hormones,
atiation, total and macronutrient calorie intake at a free choice
eal. No differences were observed between obese and over-
eight participants [34]. Alginate treatment over 10 days did
a
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ot appear to affect gastric motor functions, satiation, appetite
r gut hormones. However, other authors [35] urge caution in
xtrapolating results from the specific commercially available
roduct used by Odunsi et al. [34] to alginates in general since
oth chemical structure and concentration of the specific alginate
ource material can have effects on the gel strength [36,37].
The conflicting findings of Jensen et al. [31,33] and Odunsi
t al. [34] may be the result of different modes of alginate deliv-
ry. The greater volume of drinks compared to the volume of
apsules may stimulate gastric stretch receptors, increase satiety
nd therefore reduce energy consumption.
El Khoury et al. [38] investigated the effect of adding
trong-gelling sodium alginate to chocolate milk on glycemia,
nsulinemia, appetite and food intake. In this randomized
rossover study (see Table 1), 24 healthy men were provided with
sovolumetric (325 mL) beverages of chocolate milk, 1.25%
lginate chocolate milk, 2.5% alginate chocolate milk or 2.5%
lginate solution. The drinks were standardized for lactose,
ucrose and calcium content, and administered 120 min before
n ad libitum pizza meal during which food intake was mea-
ured. Appetite as well as plasma glucose and insulin were
easured at baseline and at intervals pre- and post-meal. Addi-
ion of 2.5% alginate to chocolate milk led to a decrease in peak
lucose concentrations, at 30 min, by an average of 6% and 13%
ompared with 1.25% alginate chocolate milk and chocolate
ilk alone, respectively. Insulin peaks at 30 min were lower by
6% after 2.5% alginate chocolate milk compared to chocolate
ilk. Pre-meal appetite was reduced dose-dependently by algi-
ate chocolate milk. Chocolate milk with 2.5% alginate reduced
ean appetite by an average of 134% in comparison with choco-
ate milk alone. However, there were no differences regarding
otal caloric intake at the pizza meal [38].
Some of the studies presented above suggest that energy
onsumption can be reduced by the dietary intake of sea-
eed isolates such as alginate. Hall and her colleagues [39]
nvestigated the effect of adding whole seaweed to bread on
nergy intake. They studied the acceptability of Ascophyllum
odosum enriched bread as part of a meal, and measured its effect
n energy consumption and nutrient absorption in overweight
ealthy men. The acceptability study including 79 untrained
ensory panelists indicated that it is acceptable to add seaweed
Ascophyllum  nodosum) to bread at concentrations of up to 4%
er 400 g wholemeal loaf. In a single blind cross over trial (see
able 1), the authors compared both energy intake and nutrient
ptake following a breakfast meal using the enriched bread (4%
. nodosum) or control bread (no A.  nodosum). Consumption
f the enriched bread at breakfast significantly reduced (16.4%)
nergy intake, but not nutrient uptake at a test meal consumed
 h later [39]. Plasma blood glucose and cholesterol levels did
ot differ between groups. The alginate in the seaweed enriched
read may have caused gastric stretching due to bulking.
.  Anti-obesity  activity  of  seaweed  components  in
nimals and  humans
Recent studies in animals have demonstrated that fucoxanthin
rom brown seaweed, for example, can reduce both body weight
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nd the percentage of white adipose tissue, suggesting that other
eaweed components besides alginate may have potential in
eight management.
Mitochondrial uncoupling protein-1 is usually expressed only
n brown adipose tissue and a key molecule for metabolic ther-
ogenesis to avoid an excess of fat accumulation [40]. Adaptive
hermogenesis by uncoupling protein-1 may be a physiological
efense mechanism against obesity [41] and the dysfunctioning
f uncoupling protein-1 has been shown to be involved in the
evelopment of obesity [42]. Little brown adipose tissue is found
n adult humans. The expression of mitochondrial uncoupling
rotein-1 in tissues other than brown adipose tissue is therefore
xpected to reduce abdominal fat. Maeda et al. [40] investigated
he effect of feeding mice Undaria  pinnatiﬁda  lipids (mainly gly-
olipids and seaweed carotenoid, fucoxanthin). While there was
ittle expression of uncoupling protein-1 in white adipose tissue
f mice fed control diet, clear signals of uncoupling protein-
 and its mRNA were observed in white adipose tissue of mice
ed Undaria lipids. In mice receiving fucoxanthin, white adipose
issue was markedly reduced and uncoupling protein-1 clearly
xpressed. No difference in white adipose tissue weight was
bserved in mice fed glycolipids.
In another publication, Maeda and his colleagues [43]
eported that abdominal white adipose tissue weights of rats and
ice fed fucoxanthin were markedly reduced compared to those
ed a control diet. The daily consumption of fucoxanthin in mice
lso significantly decreased body weight. Again clear signals of
ncoupling protein-1 and its mRNA were found in abdominal
hite adipose tissue in mice fed fucoxanthin, although there is
ittle expression of uncoupling protein-1 in white adipose tis-
ue in mice fed a control diet. These findings suggest that the
eaweed carotenoid, fucoxanthin, upregulates the expression of
ncoupling protein-1 in white adipose tissue and is an active
omponent for the anti-obesity effect of Undaria lipids [40,43].
Maeda et al. [44] also investigated the anti-obesity effects of
ucoxanthin-rich wakame lipids on high fat diet-induced obe-
ity in mice. A diet of both high fat and wakame lipids rich in
ucoxanthin markedly suppressed body weight and white adi-
ose tissue weight gain induced by a high fat diet. These results
uggest that dietary wakame lipids may ameliorate changes in
ipid metabolism induced by a high fat diet. The administration
f fucoxanthin-rich wakame lipids as a functional food may
herefore provide a biochemical and nutritional basis for the
revention of obesity.
In order to understand the mechanisms underlying the anti-
besity effects of fucoxanthin and its metabolite fucoxanthinol,
atsumoto and her colleagues [45] investigated the effects of
hese carotenoids on the absorption of triglycerides in conscious
ats implanted with cannulae into a lymph duct and the portal
r jugular vein. A duodenal infusion of test oil emulsion with
r without 2 mg of fucoxanthin or fucoxanthinol was admin-
stered in the lymph duct and the portal or the jugular vein.
he inhibitory activities of fucoxanthin and fucoxanthinol on
ancreatic lipase activity were assessed in  vitro. Increases in
ymphatic and blood triglyceride levels were much lower in
he two carotenoid-treated groups than in the carotenoid-free
roup, indicating that these marine carotenoids inhibit both
e
g
u
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ipase activity in the gastrointestinal lumen and triglyceride
bsorption [45].
Jeon et al. [46] assessed an ethanol extract of fucoxanthin-
ich seaweed in mice in regard to potential anti-obesity effects.
roups of mice received a high-fat diet supplemented with 0.2%
onjugated linoleic acid as the positive control or 1.43% or
.72% fucoxanthin-rich seaweed ethanol extract for six weeks.
he study showed that supplementation with two doses of
ucoxanthin-rich seaweed reduced body and abdominal white
dipose tissue weights, plasma and hepatic triglyceride, and/or
holesterol concentrations compared to a high-fat control group.
ctivities of adipocytic fatty acid synthesis, hepatic fatty acid
nd triglyceride synthesis, and cholesterol-regulating enzyme
ere also reduced by fucoxanthin-rich seaweed ethanol extract.
hese results indicate that fucoxanthin affects the plasma and
epatic lipid profile and body fat mass [46].
Maeda et al. [47] showed that both fucoxanthin and
ucoxanthinol inhibited intercellular lipid accumulation during
dipocyte differentiation of 3T3-L1 cells. The suppressive effect
f fucoxanthinol on the differentiation in mice of preadipocytes
o adipocytes was stronger than that of fucoxanthin [47], and the
uppressive effect of amarouciaxanthin A, a dominant metabo-
ite of fucoxanthin in white adipose tissue, was stronger than that
f fucoxanthinol [48]. Kang et al. [49] reported that fucoxan-
hin inhibited 3T3-L1 adipocyte differentiation at intermediate
nd late stages, while it enhanced adipocyte differentiation at
n early stage by affecting the expression of key adipogenic
ranscriptional regulators and inhibited glucose uptake. These
ndings suggest that fucoxanthin exerts anti-obesity effects by
nhibiting the expression of key transcriptional regulators and
lucose uptake in mature adipocytes.
The unique suppressive effect of fucoxanthin on adipocyte
ifferentiation appears to be linked to its structural properties,
ince an allenic bond is essential for the expression of this activ-
ty, and carotenoids without this bond show no activity [50]. A
ore detailed account of anti-obesity effects of fucoxanthin and
ts metabolites has been provided by Peng and co-authors [51].
Lai et al. [52] investigated the inhibitory effects of xanthigen,
ucoxanthin, and punicic acid (70% in pomegranate seed oil) on
he differentiation of 3T3-L1 preadipocytes. Xanthigen potently
nd dose-dependently suppressed accumulation of lipid droplets
n adipocytes compared to its individual components, fucoxan-
hin and pomegranate seed oil. Xanthigen down-regulated the
rotein levels of key adipogenesis transcription factors and up-
egulated various enzymes signaling in differentiated 3T3-L1
dipocytes. These findings indicate that xanthigen suppresses
dipocyte differentiation and lipid accumulation through multi-
le mechanisms and may have therapeutical benefits in obesity
52].
Administration of alginic acids from the brown macroal-
ae Sargassum  wightii  was shown to prevent the inflammatory
ell infiltration in arthritic rats by reducing the expression of
-reactive protein kinase and the corresponding increase in
nzymes linked to inflammation (e.g. cyclooxygenase, lipooxy-
enase and myeloperoxidase) [53]. This mechanism could be
seful in the treatment of obesity which appears to be associated
ith chronic low-grade inflammation [54].
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In order to investigate a beneficial role of fucoidan, extracted
rom the sporophyll of U.  pinnatiﬁda, in adipogenesis by inhibit-
ng inflammatory-related cytokines, Kim and Lee [55] assessed
he obesity-specific therapeutic action of fucoidan adipocytes.
he authors found that mRNA gene expression of key adi-
ogenic markers (adipocyte protein 2, etc.) was down-regulated
y fucoidan, and the expression of inflammation-related genes
n adipocytes during adipogenesis was reduced. In addition,
ucoidan also decreased the accumulation of lipids and reac-
ive oxygen species in adipocytes. These findings show that
ucoidan suppresses adipogenesis by inhibiting major markers
nd inflammation-related cytokines in adipocytes, suggesting
hat fucoidan may have anti-obesity effects [55].
In a study by Park et al. [56], the inhibitory effect of
ucoidan on the lipid accumulation in differentiated adipocytes
as examined. Fucoidan showed high lipid inhibition activity
t 200 g/mL concentration. Lipolytic activity in adipocytes is
ighly dependent on hormone sensitive lipase, which is one
f the most important targets of lipolytic regulation. Fucoidan
ncreased hormone-sensitive lipase expression indicating stim-
lation of lipolysis [56]. These findings suggest that fucoidan
educes lipid accumulation by stimulating lipolysis and may be
seful in the management of obesity.
Kim et al. [57] investigated the antiobesity effects of fucoidan
n an animal model of diet-induced obesity. Mice were fed
 standard diet or high-fat diet for five weeks. The animals
ere then divided into four groups, i.e. a standard diet group,
 high-fat diet group, and two high-fat diet groups contain-
ng 1% or 2% fucoidan. The fucoidan supplementation group
howed a decrease in body-weight gain, food efficiency ratio and
elative liver and epididymal fat mass compared with the high-
at diet group. The mice supplemented with fucoidan showed
educed plasma levels of triglyceride, total cholesterol and low-
ensity lipoprotein levels. In addition, fucoidan affected the
own-regulation expression patterns of epididymal adipose tis-
ue genes [57]. These results suggest that fucoidan may inhibit
dipogenesis and have a role in the control or prevention of
besity.
Stearoyl-coenzyme A desaturase-1 is a rate-limiting enzyme
hich catalyzes the biosynthesis of monounsaturated fatty acids
rom saturated fatty acids. The down-regulation of stearoyl-
oenzyme A desaturase-1 has been implicated in the prevention
f obesity and also in the improvement of insulin and lep-
in sensitivity. Beppu et al. [58] investigated the effect of the
arine caretenoid, fucoxanthin, on hepatic stearoyl-coenzyme
 desaturase-1 in obese mouse models of hyperleptinemia KK-
(y) and leptin-deficiency ob/ob. In KK-A(y) mice, a two-week
iet containing 0.2% fucoxanthin for 2 weeks significantly sup-
ressed stearoyl-coenzyme A desaturase-1 mRNA and protein
xpression in the liver. The fatty acid composition of liver lipids
as also affected, i.e. the ratio of oleic acid to stearic acid was
educed. Furthermore, serum leptin levels were significantly
ecreased in hyperleptinemia KK-A(y) mice after 2 weeks of
ucoxanthin administration. The suppressive effects of fucox-
nthin on hepatic stearoyl-coenzyme A desaturase-1 and body
eight gain were not observed in ob/ob mice [58]. These find-
ngs indicate that fucoxanthin down-regulates the expression of
t
i
l
euman Wellness 4 (2015) 87–96 93
tearoyl-coenzyme A desaturase-1 and changes the fatty acid
omposition of the liver via regulation of leptin signaling in
yperleptinemia KK-A(y) mice but not in leptin-deficient ob/ob
ice. Since a large proportion of obesity in humans is character-
zed by leptin resistance and not leptin deficiency, fucoxanthin
ay be useful in the therapy of obese individuals by maintaining
dequate homeostatic mechanisms [58].
A study by Hu et al. [59] examined the effects of com-
ined fucoxanthin and conjugated linoleic acid on high-fat
iet-induced obesity in rats. The animals were fed a high-fat
iet (control), supplemented with two doses of fucoxanthin
r low-dose fucoxanthin plus conjugated linoleic acid for 52
ays. In comparison to the control group, body weight and
hite adipose tissue weight were reduced in the combined
roup, white adipose tissue weight was decreased in the two
ucoxanthin groups. Serum total cholesterol level, triacylglyc-
rol and leptin levels were reduced in the fucoxanthin groups.
urthermore, the mRNA expression of adiponectin, adipose
riacylglycerol lipase, carnitine palmitoyltransferase 1A was up-
egulated in all fucoxanthin groups. These findings indicate that
ucoxanthin administered alone or in combination with conju-
ated linoleic acid decreases serum levels of triacylglycerol and
eptin, and fucoxanthin may exert anti-obesity effects by regu-
ating mRNA expression of enzymes related to lipid metabolism
n white adipose tissue weight of rats with diet-induced
besity [59].
Wu et al. [60] attempted to elucidate the mechanism of
ow fucoxanthin reduces adipose accumulation and studied the
ffects of fucoxanthin on metabolic rate and expressions of genes
elated to thermogenesis, mitochondria biogenesis and homeo-
tasis. Mice were fed high sucrose or high-fat diets supplemented
ith or without 0.2% fucoxanthin. Fucoxanthin increased oxy-
en consumption and carbon dioxide production and reduced
hite adipose tissue mass. Dietary fucoxanthin enhanced the
etabolic rate and lowered adipose mass irrespective of the diet.
hese effects were associated with upregulated genes of, among
thers, mitochondrial fusion in inguinal and epididymal white
dipose tissue [60].
Ha and Kim [61] investigated the effects of fucoxanthin on
ene expressions related to lipid metabolism in rats on a high-
at diet. The findings of this study indicate that fucoxanthin
onsumption decreases lipid accumulation in the liver of rats
ed a high fat diet. A fucoxanthin-enriched diet also suppressed
RNA expression of transcription factors and enzymes involved
n hepatic lipogenesis. In addition, fucoxanthin consumption
ncreased expression of enzymes that stimulate fatty acid oxi-
ation and decreased expression of cholesterol synthesizing
nzyme [61]. Fucoxanthin appears therefore to be effective in
mproving lipid metabolism in rats with a high fat diet.
The peptidyl prolyl cis/trans isomerase Pin1 has been shown
o increase the uptake of triglycerides and the differentiation of
broblasts into adipose cells in response to insulin stimulation.
 down-regulation of Pin1 may therefore be a novel approach
o prevent and treat obesity-related disorders [62]. The Pin1
nhibitor 974-B, a phlorotannin isolated from the seaweed Eck-
onia kurome, was able to inhibit the differentiation of mouse
mbryonic fibroblasts into adipose cells, suggesting that this
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ompound could be a potential drug for obesity-related disorders
62].
The promising findings of animal experiments need to be
onfirmed in humans. Abidov et al. [63] have assessed the effec-
iveness of dietary fucoxanthin supplementation for weight loss
n humans. These authors investigated the effects of xanthi-
en (brown marine algae fucoxanthin plus pomegranate seed
il) on body weight, body fat, liver lipids, and blood biochem-
stry in the weight management of 151 non-diabetic, obese
remenopausal women (113 with non-alcoholic fatty liver dis-
ase and 38 with normal liver fat) in a 16-week, double-blind,
andomized, placebo-controlled study. The administration of
anthigen-600/2.4 mg (300 mg pomegranate seed oil + 300 mg
rown seaweed extract containing 2.4 mg fucoxanthin) resulted
n a statistically significant reduction of body weight, waist cir-
umference, body and liver fat content, liver enzymes, serum
riglycerides and C-reactive protein. Fucoxanthin (>2.4 mg) and
anthigen-400/1.6 mg (200 mg pomegranate seed oil + 200 mg
rown seaweed extract containing 1.6 mg fucoxanthin) signifi-
antly increased resting energy expenditure in participants with
on-alcoholic fatty liver disease compared to placebo [63]. The
ecrease in body weight following the administration of xan-
higen may be caused by the stimulation of resting energy
xpenditure and by anti-inflammatory and metabolism normal-
zing mechanisms.
.  Limitations  of  existing  studies  and  suggestions  for
uture research
The incidence of the metabolic disorders including obesity
s increasing worldwide and has reached epidemic proportions
n developed countries, with notable exceptions of some South-
ast Asian countries where seaweeds are part of the staple diet.
owever, basing the utility of seaweeds in the prevention and
ontrol of obesity on epidemiological evidence is problematic
ue to general differences in dietary habits and since a wide range
f herbal plants associated with anti-obesity effects (e.g. black
ea, catechin-enriched green tea, oolong tea) are also commonly
onsumed in Southeast Asia [64,65].
Medicinal plants and plant metabolites are thought to harbor
otential anti-obesity compounds which may be able to prevent
eight gain or promote weight loss [66]. Dietary seaweed fibers
re of particular interest in the management of obesity and a
roposed mechanism of action is the modulation of nutrient
ptake from the small intestine. Most published studies avail-
ble suggest that alginate consumption affects satiety feelings
nd energy intake. However, studies investigating the effects of
lginate preparations in animals and humans have been of short
uration. This means that long-term effects on appetite and
nergy intake cannot be assessed. In addition, further assessment
n regard to the volume of alginate administered is needed.
A major drawback in regard to the evaluation of anti-obesity
ffects of seaweeds is the fact that most experiments were per-
ormed in  vitro  or in  vivo  using animal models. The results of
hese studies cannot be extrapolated to humans and may there-
ore have no therapeutic consequences. A sufficient number of
ell-controlled studies in human subjects are still lacking. A
i
t
g
iuman Wellness 4 (2015) 87–96
rst study by Abidov et al. [63] assessed the effects of a 16-
eek administration of xanthigen on body weight, body fat and
ther parameters in the weight management of obese female
articipants. The design and methodology of this double-blind,
andomized, placebo-controlled study were sound. However,
ufficiently powered long-term studies including both sexes and
arious age groups are needed in order to evaluate the efficacy
f seaweed compounds in the prevention and control of obesity
n human participants.
Several problems in regard to the use of seaweeds in the
reatment of obesity need to be addressed by future research.
hese problems include the description of the underlying bioac-
ive principles, the definition of oral bioavailability of the active
ompounds and the assessment of therapeutic doses. Various
ndings suggest that fucoxanthin might act as a regulator of
ipid metabolism in fat tissues [67]. However, the bioavailabil-
ty of fucoxanthin in brown seaweeds was shown to be low in
uman subjects [51]. Orally administered fucoxanthin is metab-
lized into fucoxanthinol and amarouciaxanthin A in mice and
hese and other metabolites in humans should be investigated in
egard to the bioactivity of fucoxanthin. Different concentrations
nd compositions of bioactive compounds present in different
eaweed species may contribute to potential anti-obesity effects.
he role of these parameters needs therefore to be evaluated in
ore extensive animal experiments and well-controlled clinical
rials.
Seaweeds are mixtures of partly defined complex chemicals
nd this complexity makes the discovery of novel therapeutic
ubstances difficult. Well defined and standardized mixtures of
ioactive ingredients from seaweeds (nutraceuticals) should be
nvestigated in  vitro, in animal models of obesity and in over-
eight and obese human subjects.
Solid evidence indicating that seaweeds are effective in long-
erm weight management is still lacking. The effective non-toxic
oses of seaweed preparations need to be defined by future
nvestigations. A particular problem is bioavailability since suffi-
ient amounts of orally administered nutraceuticals are required
or adequate efficacy. Large-scale, sufficiently powered, well-
esigned, randomized controlled trials in clinical and home
ettings are required to investigate the putative effects of seaweed
omponents. Improvements in future study designs regarding
ample size, duration, parameters measured and full reporting
ill allow more definitive conclusions concerning the therapeu-
ic value of seaweed in the management of obesity.
.  Conclusion
The therapeutic utilization of marine bioactive substances
ncluding seaweeds is common in Asia. Potential benefits of
eaweed consumption have been reported, among others, in the
anagement of body weight and obesity.
The majority of acute studies assessing the short-term effects
f dietary alginate supplementation indicate that alginate may
ncrease satiety, reduce energy intake and support weight reduc-
ion. Mechanisms proposed for these effects include delayed
astric clearance, stimulation of gastric stretch receptors,
ncreased viscosity of digesta and attenuated nutrient absorption.
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owever, long-term studies in humans are required in order to
llow firm conclusions to be drawn in regard to anti-obesity
ffects of alginate intake and their underlying mechanisms.
Numerous studies in animals have investigated the potential
nti-obesity effects of seaweed on a wide range of parame-
ers including the reduction of adipogenesis and the inhibition
f major lipid and carbohydrate hydrolyzing and metabolizing
nzymes. In addition, anti-inflammatory properties of seaweed
ompounds such as alginic acids may support the therapy of
besity which seems to be associated with chronic inflamma-
ion [54]. The results of the available studies suggest beneficial
ffects of seaweed components such as fucoxanthin. However,
t is premature to extrapolate these findings to humans. Human
ata suggest that xanthigen may be a promising food supple-
ent in regard to the treatment of obesity [63]. Future studies
re required in order to confirm the importance of this finding
n the long-term weight management in humans. In addition,
t needs to be established whether seaweed consumption exerts
nti-obesity effects in different populations. For example, the
enes encoding enzymes that are able to digest seaweed are
resent in the microbiota of the Japanese endogenous popula-
ion and absent in North American individuals. These genes
riginate from marine microbes present on seaweed consumed
68].
In summary, the data available at present suggest potential
enefits on obesity of seaweed and seaweed components. Future
nvestigations are required to establish the therapeutic efficacy
n humans and elucidate the mechanisms of actions.
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